Tussionex Articles
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
Belgium’s UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
1 February 2010
UCB revenue falls on drop in US sales
1 May 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
FDA issues warning on UCB's cough medicine
24 March 2008
Celltech sees sales rise 6% in 2003
22 March 2004
UPDATE- Pretax profits up at Celltech in 2002
24 March 2003
Celltech pretax profits leap 90%
18 March 2002
Medeva confident about its future
12 February 1999
UK's Medeva Redefining Product Portfolio
18 February 1998
Strong Growth In 1996 As Medeva Builds In the USA
24 February 1997
Concerns Around Medeva Acquisition
24 June 1996
Showing 1-12 of 12 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
